A young man presenting with recurrent nephrolithiasis

Rachel Hellemans, Gert A. Verpooten and Jean-Louis Bosmans

Department of Nephrology-Hypertension, Antwerp University Hospital, Belgium

Correspondence and offprint requests to: Rachel Hellemans; E-mail: rachel.hellemans@uza.be

Keywords: Dent’s disease; hypercalciuria; nephrocalcinosis; renal cysts

Introduction

We present a patient with recurrent nephrolithiasis, nephrocalcinosis, renal impairment, heavy proteinuria and multiple renal cysts. We focused on the differential diagnosis of nephrocalcinosis, which led us to the rare entity of Dent’s disease. This diagnosis was confirmed by molecular analysis, revealing a mutation in the CLCN5 gene.

Case

A male patient, born in 1990, first presented with a kidney stone when he was 10 years old, but the stone had passed spontaneously, and no further testing was done at that time. At the age of 20, he presented with a second episode of renal colic. Proteinuria and microscopic haematuria were also noticed, for which he was referred to a nephrologist.

On examination, he was a lean young man with normal height and stature. Height was 175 cm, and weight was 59 kg. Systemic examination was unremarkable. Blood pressure was 107/74 mmHg.

Laboratory examination showed an elevated serum creatinine of 130 μmol/L (1.44 mg/dL) (eGFR 62 mL/min/1.73 m²). Serum alkaline phosphatase level was 122 U/L with elevated bone fraction of alkaline phosphatase. Other blood tests were normal. Twenty-four-hour urine collection showed proteinuria of 2.981 g/day consisting mainly of low-molecular-weight proteins. Calciuria was 8.3 mmol/day (334 mg/day) or 5.7 mg/kg/day (normal <4). Urine sediment analysis was normal (Table 1).

Ultrasonography, CT scan and MRI revealed normal kidney size and contour but bilateral multiple cysts. The cysts were mainly localized in the cortex, and they had a benign simple appearance. Furthermore, bilateral nephrolithiasis and intraparenchymal calcification consistent with nephrocalcinosis were seen (Figures 1 and 2).

Renal biopsy had been performed in another centre and had shown normal light microscopy, normal electron microscopy, and negative immunofluorescence.

After the acute renal colic, transurethral stone extraction was performed. Stone analysis showed a stone consisting of calcium phosphate and calcium oxalate.

Family history was negative for renal disease or renal colic. The patient had no siblings. The parents underwent a renal ultrasound examination: both had normal morphology of their kidneys without cysts, but one asymptomatic nephrolithiasis was found in the father.

Discussion

Our differential diagnosis included disorders resulting in nephrocalcinosis. This term is used to describe the deposition of calcium in the renal parenchyma and tubules. It is caused by an increase in the urinary excretion of calcium, phosphate and/or oxalate. Hypocitraturia also may contribute. Underlying conditions can be categorized into those that cause hypercalciuria with hypercalcaemia, hypercalciuria without hypercalcaemia, hyperphosphaturia, or hyperoxaluria (Table 2).

Our patient presented with nephrocalcinosis in the absence of hypercalcaemia. He had no hypercalcaemia, hyperparathyroidism, hyperphosphaturia or hyperoxaluria, which narrows our differential diagnosis down to (inherited) tubulopathies, chronic hypokalaemia, medullary sponge kidney or sarcoidosis. The normal serum bicarbonate practically rules out RTA type 1, and the absence of hypokalaemia or alkalosis makes Bartter’s syndrome very unlikely. Since there is no hypocalcaemia or hypomagnesaemia, other inherited tubulopathies such as autosomal dominant hypocalcaemia or hypomagnesaemia, and hypercalciuric nephrocalcinosis can also be excluded. Moreover neither of these aforementioned disorders are associated with heavy low-molecular-weight proteinuria. Sarcoidosis can also result in hypercalciuria and nephrocalcinosis, sometimes without overt hypercalcaemia, but since the biopsy did not show granulomatous interstitial nephritis or glomerular disease, the proteinuria could not be explained. Patients with medullary sponge kidney present with nephrocalcinosis and renal cysts, bringing us closer to this patient’s situation. But in the medullary sponge kidney, cysts would be confined to the renal medulla which is not the case here,
nor would we expect heavy proteinuria or diminished renal function in this disease.

Hereditary renal cystic diseases were also considered. The parents did not have renal cysts, ruling out autosomal dominant inheritance. Moreover, none of the genetic disorders typically presenting with renal cysts is associated with either heavy proteinuria or hypercalciuria.

There is only one disease that perfectly matches with our patient’s abnormalities, which is Dent’s disease. The term Dent’s disease, first introduced in 1990 [1], identifies a group of X-linked renal disorders characterized by low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis and/or nephrolithiasis and progressive renal failure [1]. It is a hereditary tubulopathy, in the large majority of cases caused by a mutation in the CLCN5 gene. Multiple renal cysts have been reported in Dent’s disease [1], although they are not commonly used as a diagnostic feature.

In this patient, the diagnosis was confirmed by molecular analysis, revealing a mutation in the CLCN5 gene (c.815A>G). The same mutation was found in the mother. This mutation has been reported before [2].

**Dent’s disease**

The term Dent’s disease, first introduced in 1990 [1], identifies a group of X-linked renal disorders characterized by low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis and/or nephrolithiasis and progressive renal failure. The disease also may be associated with aminoaciduria, phosphaturia, glycosuria, kaliuresis, uricosuria, and impaired urinary acidification, and is complicated by rickets or osteomalacia in some patients. Thus, Dent’s disease may be considered a form of the renal Fanconi syndrome [1]. In the majority of cases, the disease is caused by a mutation in the CLCN5 gene (c.815A>G). The same mutation was found in the mother. This mutation has been reported before [2].

**Dent’s disease**

The term Dent’s disease, first introduced in 1990 [1], identifies a group of X-linked renal disorders characterized by low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis and/or nephrolithiasis and progressive renal failure. The disease also may be associated with aminoaciduria, phosphaturia, glycosuria, kaliuresis, uricosuria, and impaired urinary acidification, and is complicated by rickets or osteomalacia in some patients. Thus, Dent’s disease may be considered a form of the renal Fanconi syndrome [1]. In the majority of cases, the disease is caused by a mutation in the CLCN5 gene (c.815A>G). The same mutation was found in the mother. This mutation has been reported before [2].

**Table 1. Laboratory examinations**

| Serum/blood concentration | Normal value     | 24-h urine collection | Normal value     |
|----------------------------|------------------|-----------------------|------------------|
| BUN                        | 6.1 mmol/L (3.0–6.5) | Volume 2960 mL       |                  |
| Creatinine                 | 130 μmol/L (50–110)  | Sodium 178 mmol/day (40–220) |                  |
| MDRD                       | 62 mL/min/1.73 m²  | Potassium 72 mmol/day (25–125) |                  |
| Sodium                     | 142 mmol/L (137–145) | Glucose Below detection limit |                  |
| Potassium                  | 3.7 mmol/L (3.5–5.0)  | Creatinine 12.8 mmol/day (8.8–17.6) |                  |
| Chloride                   | 103 mmol/L (98–107)  | Calcium 8.3 mmol/day (<6.2) |                  |
| Bicarbonate + CO₂          | 26 mmol/L (23–30)  | Inorganic phosphate 42 mmol/day (12.9–42.0) |                  |
| Calcium                    | 2.42 mmol/L (2.20–2.58) | Magnesium 3.2 mmol/day (3.0–5.0) |                  |
| Inorganic phosphate        | 0.97 mmol/L (0.80–1.60) | Oxalic acid 310 μmol/day (110–440) |                  |
| Magnesium                  | 0.94 mmol/L (0.80–1.20) | Citric acid 3.77 mmol/day (2.12–6.26) |                  |
| UrIC acid                  | 240 μmol/L (120–420)  | Total protein 2.981 g/day (<0.15) |                  |
| Albumin                    | 52 g/L (40–60)  | Protein electrophoresis Mixed tubular/glomerular |                  |
| Total protein              | 76 g/L (60–80)  | Immunofixation proteinuria (mainly LMW proteins) |                  |
| Alkaline                   | 122 U/L (36–95)  | Phosphatase 2.2 pmol/L (1.2–5.8) |                  |
| Phosphatase                | 2.2 pmol/L (1.2–5.8)  | Intact PTH 62 mmol/L (45–90) |                  |
| Intact PTH                 |                    | Urine spot test Cystine qualitative test Negative |                  |
| 25-OH vitamin D            |                    | pH 7.0 |                  |
Many affected men progress to end-stage renal failure between the third and fifth decades of life. The pathophysiology of Dent’s disease is still incompletely understood. Mutations in the CLCN5 gene lead to inactive CLC-5 chloride channel function. In the human kidney, CLC-5 is primarily expressed in proximal tubular cells, in cortical collecting duct intercalated cells and also in the thick ascending limb of Henle’s loop [6]. In proximal cells, CLC-5 is predominantly located in the subapical endosomes, which are involved in the endocytotic reabsorption of low-molecular-weight (LMW) proteins that have passed the glomerular filter. CLC-5 allows for acidification of the endosomes; dysfunctional CLC-5 results in impaired acidification and failure to process adsorbed proteins. This may also lead to impaired recycling of endosomal membrane back to the apical surface [7]. This explains the LMW proteinuria in patients with Dent’s disease. However, the mechanism by which CLCN5 mutations result in hypercalciuria remains to be elucidated. Also, the cause of renal function impairment in Dent’s disease is not completely understood. Although renal calcification was first suspected to be involved in the decline in renal function, hypercalciuria and nephrolithiasis have been shown to be of poor predictive value in identifying individuals at risk for developing renal insufficiency [8].

To date, >85 different nonsense or missense mutations, insertions, or deletions in the CLCN5 gene have been reported in the literature, meaning that the spectrum of CLCN5 mutations is highly varied [2]. There is no correlation found between the nature of the mutation and the presence of particular clinical features or the overall severity of the disease.

Treatment measures are mostly supportive. Although it is unknown to what extent hypercalciuria is responsible for the renal failure in Dent’s disease, it is the major factor promoting nephrolithiasis. Therefore, an attempt to reduce calcium excretion is reasonable. This can be done by restricting dietary sodium intake (since sodium excretion promotes calcium excretion) and by administering a thiazide diuretic. Thiazides reduce the rate of calcium stone recurrence in patients with idiopathic hypercalciuria [9], and a similar correction of hypercalciuria has been shown in patients with Dent’s disease [10]. However, because severe hypokalaemia can be seen in these patients using only moderate doses of thiazide diuretics [11], starting with small doses and regular electrolyte controls is mandatory. In a mouse model of Dent’s disease, a diet high in citrate showed a delayed progression of renal failure, possibly by enhancing calcium solubility in the urine [12].

Early diagnosis could theoretically help to prevent the progression to end-stage renal disease, but the clinical diagnosis of Dent’s disease is often difficult since patients may have only mild clinical and biochemical signs, and the X-linked inheritance is not always obvious.Carrier mothers or daughters of an affected male may not present LMW proteinuria [13]. CLCN5 mutations are demonstrated in >85% of patients, when the clinical diagnosis of Dent’s disease is made based on the concurrence of LMW proteinuria, hypercalciuria and nephrocalcinosis [2].

Other treatment options are limited and depend on the specific clinical manifestation of the disease. For example, patients with renal stones may benefit from a diet rich in citrate, which can decrease calcium solubility in the urine. However, this approach is not always effective and may be accompanied by side effects such as nausea and vomiting. In severe cases, renal replacement therapy may be necessary. In addition, renal transplant may be considered as a treatment option, but the long-term outcome is unpredictable.

Table 2. Differential diagnosis of nephrocalcinosis

| Hypercalciuria with hypercalcaemia<sup>a</sup> | Hypercalciuria without hypercalcaemia |
|-----------------------------------------------|--------------------------------------|
| Primary hyperparathyroidism                    | Type 1 (distal) renal tubular acidosis (inherited or secondary) |
| Sarcoïdosis (or other granulomatous disease)   | Medullary sponge kidney               |
| Vitamin D therapy                             | Loop diuretics                        |
| Milk alkali syndrome                          | Nephrocalcinosis in premature infants |
|                                               | Chronic hypokalaemia                  |
|                                               | Inherited tubulopathies               |
|                                               | Bartter’s syndrome                    |
|                                               | Hypomagnesaemic hypercalciuric nephrocalcinosis |
|                                               | Autosomal dominant hypocalcaemia      |
|                                               | Dent’s disease                        |
|                                               | Lowe syndrome                         |
|                                               | Idiopathic hypercalciuria            |
| Hyperphosphaturia                              |                                      |
| Inherited tubulopathies                        |                                      |
| X-linked hypophosphataemic rickets             |                                      |
| Autosomal dominant hypophosphataemic rickets   |                                      |
| Hereditary hypophosphataemic rickets with hypercalciuria |                                      |
| Dent’s disease                                 |                                      |
| Lowe syndrome                                 |                                      |
| Acquired renal phosphate wasting               |                                      |
| Tumour-induced osteomalacia                    |                                      |
| Renal transplant                               |                                      |
| Acute phosphate nephropathy                    |                                      |
| Oral sodium phosphate bowel preparations       |                                      |
| Tumour lysis syndrome                          |                                      |

<sup>a</sup>Although a minority of patients may be intermittently or persistently normocalcaemic.
with multiple renal cysts on medical imaging techniques. Multiple renal cysts have been reported in Dent’s disease [1], although they are not commonly used as a diagnostic feature.

**Conclusion**

In summary, this young man presented with renal impairment, low-molecular-weight proteinuria, hypercalciuria, nephrolithiasis, nephrocalcinosis and multiple renal cysts. Furthermore, the persistently elevated serum alkaline phosphatase level suggested abnormal bone metabolism. This phenotype was consistent with Dent’s disease. The diagnosis was confirmed by molecular analysis, revealing a mutation in the CLCN5 gene. Besides displaying the classical diagnostic criteria of Dent’s disease, our patient presented with multiple renal cysts. Although multiple renal cysts have been reported in Dent’s disease, they are not commonly used as a diagnostic feature. Other observations are needed to explore the possible correlation between the nature of the mutation and the cystic phenotype of Dent’s disease.

**Teaching points**

(1) Nephrocalcinosis indicates an increase in the urinary excretion of calcium, phosphate and/or oxalate. Underlying conditions can be categorized into those that cause hypercalciuria with hypercalcaemia, hypercalciuria without hypercalcaemia, hyperphosphaturia, or hyperoxaluria.

(2) Dent’s disease is a hereditary tubulopathy, in the large majority of cases caused by a mutation in the CLCN5 gene. It is characterized by X-linked inheritance, low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis and/or nephrolithiasis and progressive renal failure.

(3) Dent’s disease can present with multiple renal cysts, and may be considered in the differential diagnosis of cystic renal disease.

**Conflict of interest statement.** None declared.

**References**

1. Wrong OM, Norden AGW, Feest TG. Dent's disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. *Quart J Med* 1994; 87: 473–493

2. Tosetto E, Ghiggeri GM, Emma F et al. Phenotypic and genetic heterogeneity in Dent’s disease—the results of an Italian collaborative study. *Nephrol Dial Transplant* 2006; 21: 2452–2463

3. Lloyd SE, Pearce SH, Fisher SE et al. A common molecular basis for three inherited kidney stone diseases. *Nature* 1996; 379: 445–449

4. Hoopes RR Jr, Shrimpton AE, Knohl SJ et al. Dent disease with mutations in ORCL1. *Am J Hum Genet* 2005; 76: 260–267

5. Reinhart SC, Norden AGW, Lapsley M et al. Characterization of carrier females and affected males with X-linked recessive nephrolithiasis. *J Am Soc Nephrol* 1995; 5: 1451–1461

6. Devuyst O, Christie PT, Courtoy PJ et al. Intra-renal and subcellular distribution of the human chloride channel, CLC-5, reveals a pathophysiological basis for Dent’s disease. *Hum Mol Genet* 1999; 8: 247–257

7. Christensen EI, Devuyst O, Dom G et al. Loss of chloride channel ClC-5 impairs endocytosis by defective trafficking of megalin and cubulin in kidney proximal tubules. *Proc Natl Acad Sci USA* 2003; 100: 8472–8477

8. Kelleher CL, Buckalew VM, Frederickson ED et al. CLCN mutation Ser244Leu is associated with X-linked renal failure without X-linked recessive hypophosphatemic rickets. *Kidney Int* 1998; 53: 31–37

9. Roe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. *Ann Intern Med* 1977; 87: 404–410

10. Raja KA, Schurman S, D’Mello RG et al. Responsiveness of hypercalciuria to thiazide in Dent’s disease. *J Am Soc Nephrol* 2002; 13: 2938–2944

11. Scheinman SJ. X-linked hypercalciuric nephrolithiasis: clinical syndromes and chloride channel mutations. *Kidney Int* 1998; 53: 3–17

12. Cebotaru V, Kaul S, Devuyst O et al. High citrate diet delays progression of renal insufficiency in the CIC-5 knockout mouse model of Dent’s disease. *Kidney Int* 2005; 68: 642–652

13. Norden AGW, Scheinman SJ, Deschoot-Laneckman MM et al. Tubular proteinuria defined by a study of Dent’s (CLCN5 mutation) and other tubular diseases. *Kidney Int* 2000; 57: 240–249